Status:
COMPLETED
Clinical Trial of Pentoxifylline in Patient With Cirrhosis
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Cirrhosis
Liver Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
In patients with cirrhosis and liver failure, pro-inflammatory cytokines (TNF alpha) might be responsible of severe complications and death. Thus, the prevention of cytokine production should prevent ...
Detailed Description
The aim of this study is to study the 2 months survival rate in patients with severe cirrhosis (Child-Pugh C) with pentoxifylline - an inhibitor of cytokine production. The 6 month mortality, the prop...
Eligibility Criteria
Inclusion
- adult patient of more than 18 years
- child pugh C cirrhosis
Exclusion
- pregnant woman
- Patient received anticoagulant
- Patient treated for arterial hypertension
- Patient with severe coronaropathy
- Patient with hyper sensibility of pentoxifylline
- Patient hospitalized for less 24 hours
- Patient admitted for a treatment of hepatocellular-carcinoma or COLLANGIO- carcinoma
- Patient with HIV
- Patient who has been transplanted
- Patient treated with immuno- suppressors
- Patient who has already received pentoxifylline for 3 months before inclusion
- Patient for whom the follow-up is considered impossible
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT00162552
Start Date
August 1 2004
End Date
December 1 2007
Last Update
January 17 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Beaujon
Clichy, France, 92110